Allogene Pretax Profit Margin from 2010 to 2024
| ALLO Stock | USD 2.89 0.03 1.05% |
Pretax Profit Margin | First Reported 2010-12-31 | Previous Quarter -3.4 K | Current Value -3.6 K | Quarterly Volatility 1.3 K |
Check Allogene Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allogene main balance sheet or income statement drivers, such as Interest Expense of 20.7 M, Selling General Administrative of 61.1 M or Total Revenue of 90.2 K, as well as many exotic indicators such as Price To Sales Ratio of 5.6 K, Dividend Yield of 0.0 or PTB Ratio of 0.93. Allogene financial statements analysis is a perfect complement when working with Allogene Therapeutics Valuation or Volatility modules.
Allogene | Pretax Profit Margin |
Latest Allogene Therapeutics' Pretax Profit Margin Growth Pattern
Below is the plot of the Pretax Profit Margin of Allogene Therapeutics over the last few years. It is Allogene Therapeutics' Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Allogene Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Pretax Profit Margin | 10 Years Trend |
|
Pretax Profit Margin |
| Timeline |
Allogene Pretax Profit Margin Regression Statistics
| Arithmetic Mean | (567.40) | |
| Coefficient Of Variation | (220.91) | |
| Mean Deviation | 897.16 | |
| Median | (6.68) | |
| Standard Deviation | 1,253 | |
| Sample Variance | 1.6M | |
| Range | 3.6K | |
| R-Value | (0.67) | |
| Mean Square Error | 928,630 | |
| R-Squared | 0.45 | |
| Significance | 0.01 | |
| Slope | (188.26) | |
| Total Sum of Squares | 22M |
Allogene Pretax Profit Margin History
About Allogene Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Allogene Therapeutics income statement, its balance sheet, and the statement of cash flows. Allogene Therapeutics investors use historical funamental indicators, such as Allogene Therapeutics's Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Although Allogene Therapeutics investors may use each financial statement separately, they are all related. The changes in Allogene Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Allogene Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Allogene Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Allogene Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | -3.4 K | -3.6 K |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Allogene Stock
| 0.64 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
| 0.56 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.47 | ELYM | Eliem Therapeutics Upward Rally | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Allogene Therapeutics Correlation against competitors. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Allogene Stock analysis
When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.55) | Return On Assets (0.27) | Return On Equity (0.56) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.